IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that company management will present at the following conferences in March.
-
Cowen and Company 37th Annual Health Care Conference
- Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer
- Presentation Type: Corporate Overview
- Presentation Date: Tuesday, March 7, 2017
- Presentation Time: 10:00am E.T.
- Location: Boston, MA
-
29th Annual ROTH Conference
- Presenter: Thomas Mitro, President and Chief Operating Officer
- Presentation Type: Corporate Overview
- Presentation Date: Tuesday, March 14, 2017
- Presentation Time: 1:30pm P.T.
- Location: Dana Point, CA
-
Oppenheimer's 27th Annual Healthcare Conference
- Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer
- Presentation Type: Fireside
- Presentation Date: Tuesday, March 21, 2017
- Presentation Time: 2:45pm E.T.
- Location: New York, NY
The presentations and fireside discussion will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of each webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% was resubmitted in February 2017. The second product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of RhopressaTM and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM NDA filing is expected to take place in late 2017 or early 2018. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.